Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Reports Skyhawk's agreement with Genentech, a member of the Roche Group, granting an exclusive worldwide license across multiple oncology and neurological…
Coverage emphasized the up-to-$2B biobucks value across multiple targets, positioning Skyhawk as a leading player in the emerging small-molecule RNA-splicing…
BioSpace noted Skyhawk's RNA-splicing technology had drawn repeat large-pharma interest including expanded Merck and Vertex deals, validating the platform…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Skyhawk Therapeutics and Genentech (Roche) entered a multi-target exclusive option and license agreement for small-molecule RNA splicing modifiers using Skyhawk's SkySTAR platform. Skyhawk received an undisclosed upfront and is eligible for milestone and royalty payments with biobucks potential of approximately $2B across targets. Genentech leads clinical development and commercialization.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Skyhawk Therapeutics Inc. (this deal) | 2019 | $2.0B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2019 deals · Roche Holding AG deals · Neurology deals